Banner Publications MH200828 N141

Publications

Results found: 1000

Showing results: 1 - 50

Investigational new drugs

Extrahepatic metabolism of ibrutinib.

01-02-2021
Key
Clinical and translational science

A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens.

23-11-2022
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue.

15-11-2022
Biomedical chromatography : BMC

Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

01-11-2022
Clinical pharmacokinetics

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.

11-10-2022
Biomedical chromatography : BMC

Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs.

08-10-2022
Frontiers in oncology

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?

04-10-2022
Pharmaceutical research

Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting.

01-10-2022
Breast cancer research and treatment

The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer.

01-10-2022
Annals of oncology : official journal of the European Society for Medical Oncology

Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study.

01-10-2022
Pharmaceuticals (Basel, Switzerland)

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure.

08-09-2022
Immuno-oncology technology

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

01-09-2022
International journal of molecular sciences

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

30-08-2022
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue.

15-08-2022
Therapeutic drug monitoring

Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with Cancer.

01-08-2022
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability.

01-08-2022
Clinical and translational science

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer.

01-08-2022
Clinical pharmacology and therapeutics

Presence of Five Chemotherapeutic Drugs in Breast Milk as a Guide for the Safe Use of Chemotherapy During Breastfeeding: Results From a Case Series.

01-08-2022
Pharmaceuticals (Basel, Switzerland)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs.

13-07-2022
Cancer chemotherapy and pharmacology

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies.

01-07-2022
Clinical pharmacology and therapeutics

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.

01-07-2022
Journal of pharmaceutical and biomedical analysis

A highly sensitive bioanalytical method for the quantification of vinblastine, vincristine, vinorelbine and 4-O-deacetylvinorelbine in human plasma using LC-MS/MS.

05-06-2022
Cancer chemotherapy and pharmacology

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.

01-06-2022
Cancer chemotherapy and pharmacology

Is age just a number? A population pharmacokinetic study of gemcitabine.

01-05-2022
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Optimized sample pre-treatment procedure for the simultaneous UPLC-MS/MS quantification of ipilimumab, nivolumab, and pembrolizumab in human serum.

30-04-2022
Pharmacological research

ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.

01-04-2022
Pharmacological research

ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.

01-04-2022
Pharmaceutical research

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib.

01-04-2022
Drug metabolism and disposition: the biological fate of chemicals

Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.

01-04-2022
Frontiers in pharmacology

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.

22-03-2022
Journal of pharmaceutical sciences

Population Pharmacokinetic Modelling to Support the Evaluation of Preclinical Pharmacokinetic Experiments with Lorlatinib.

01-02-2022
Clinical pharmacology and therapeutics

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.

01-02-2022
BMC cancer

The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

25-01-2022
Journal of pharmaceutical and biomedical analysis

Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue.

05-01-2022
Journal of pharmaceutical and biomedical analysis

Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates.

05-01-2022
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib.

01-01-2022
Drugs

Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer.

01-01-2022
International journal of antimicrobial agents

An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.

01-01-2022
Targeted oncology

Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.

01-01-2022
Clinical cancer research : an official journal of the American Association for Cancer Research

Precision Dosing of Targeted Therapies Is Ready for Prime Time.

15-12-2021
Molecular pharmaceutics

P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.

06-12-2021
Clinical pharmacokinetics

Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review.

01-11-2021
Clinical pharmacology and therapeutics

Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence".

01-11-2021
Clinical pharmacokinetics

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.

01-11-2021
Pharmaceuticals (Basel, Switzerland)

P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).

27-10-2021
Journal of pharmaceutical and biomedical analysis

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS.

25-10-2021
Pharmaceutics

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability.

21-10-2021
NPJ breast cancer

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.

20-10-2021
Drug and alcohol dependence

The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review.

01-10-2021
Pharmacological research

ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.

01-10-2021

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.